Clariborol Intermediates (CAS 1187188-60-8) | High-Purity API Building Blocks for Psoriasis & Dermatitis Drug Development
Overview
Clariborol Intermediates are pharmaceutical-grade chemical compounds essential for synthesizing Crisaborole, a non-steroidal PDE4 inhibitor approved for psoriasis and atopic dermatitis treatment12. With ≥98% purity (HPLC/GC-MS validated), these intermediates meet stringent USP/EP standards for API manufacturing and preclinical research12.
Key Applications
🔬 Drug Development:
🧪 Research Use:
Product Specifications
✅ Purity: ≥98% (certified by COA with residual solvent <50 ppm)12.
⚪ Form: White to off-white crystalline powder2.
📦 Packaging: Bulk quantities (1-25 kg) or lab-scale units (100 g, 500 g)13.
🌡️ Storage: Stable for 24 months at 2-8°C in airtight, light-resistant containers24.
Quality & Compliance
📄 Pharmaceutical Compliance: Manufactured under GMP guidelines for API intermediates24.
🔍 Analytical Reports: Includes heavy metals (<10 ppm), microbial limits, and chiral purity testing24.
Supply Benefits
🌍 Global Availability: Ready stock in EU, US, and Asia warehouses for fast delivery13.
🔧 Custom Solutions: Tailored packaging (e.g., nitrogen-sealed vials) and documentation support23.
Keywords: Clariborol Intermediates CAS 1187188-60-8, Crisaborole API Precursors, Psoriasis Drug R&D, PDE4 Inhibitor Synthesis, GMP Pharmaceutical Intermediates12.
China
